echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > The team of Professor Kong Wei/Professor Wu Hui has made new progress in the field of Alzheimer's pathogenesis

    The team of Professor Kong Wei/Professor Wu Hui has made new progress in the field of Alzheimer's pathogenesis

    • Last Update: 2022-11-15
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
      

    The team of Professor Kong Wei/Professor Wu Hui, National Engineering Laboratory of AIDS Vaccine, College of Life Sciences, Jilin University, has made new progress
    in the field of Alzheimer's pathogenesis 。 The study has been published in the Journal
    of Neuroinflammation today under the title "Hyperphosphorylated tau mediates neuronal death by inducing necroptosis and inflammation in Alzheimer's disease.
    "

    Alzheimer's disease (AD) is the world's most widespread and most common chronic developing neurodegenerative disease
    in older adults.
    The clinical manifestations are a deterioration of cognitive and memory functions, and a slow decline
    in the ability to perform daily living.
    However, the current treatment methods can only improve the symptoms of AD patients and cannot fundamentally block the disease process, so elucidating the pathogenesis of AD is of great significance
    for drug development.
    Neurofibrillary tangles (NFTs) are one of the main pathological features of AD and consist of
    hyperphosphorylated tau proteins.
    Overphosphorylated tau protein can disrupt the stability of microtubules, affect axon transport and damage neurons, but the specific mechanism by which phosphorylated tau leads to neuronal death needs to be further elucidated
    .
    Previous studies have shown that RIPK1, a key factor in the regulation of programmed necrosis in the brain of AD patients, is significantly upregulated and MLKL dimerization is increased, but how programmed necrosis in AD brain is triggered and the related regulatory mechanism is not clear
    .
    Therefore, the research team first confirmed that phosphorylated tau protein can upregulate RIPK1, RIPK3 and MLKL in mouse hippocampal neurons HT22 and human neuroblastoma SY-SY5Y, promote the formation of necrosomes and thus trigger programmed necrosis
    .
    Next, transcriptome sequencing results showed that there was significant upregulation of inflammatory factors during phosphorylated tau-induced necrosis, and CRISPR-Cas9 knockout experiments showed that the inflammatory response was mediated
    by the RIPK1-RIPK3-MLKL axis.
    Further studies have found that the NF-κB signaling pathway responds to the activation of the RIPK1-RIPK3-MLKL axis and thus promotes the transcription
    of multiple inflammatory factors.
    In vivo experiments also confirmed that the treatment of Nec-1s, an inhibitor of RIPK1, in AD model mice inhibited the occurrence of programmed necrosis and the activation of microglia, and alleviated memory and cognitive impairment
    in model mice.

    The first thesis was completed by Jilin University, and the first author was Dong Yue
    , a graduate student from the College of Life Sciences, Jilin University.
    Professor Kong Wei and Professor Wu Hui of the National Engineering Laboratory of AIDS Vaccine, College of Life Sciences, Jilin University, are the co-corresponding authors
    of the paper.
    This research work was supported
    by the National Natural Science Foundation of China and the Natural Science Foundation of Jilin Province.

    Full text link: https://doi.
    org/10.
    1186/s12974-022-02567-y


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.